Introduction
============

Hepatocellular carcinoma (HCC) is a very common malignancy worldwide, and approximately half of the new cases and deaths reported yearly are believed to occur in the People's Republic of China.[@b1-ott-7-957] The main causes of HCC in the People's Republic of China are chronic hepatitis B and C virus infections, that result in hepatic cirrhosis, often accompanied by portal hypertension and secondary hypersplenism.[@b2-ott-7-957] Hypersplenism has often been considered a contraindication to liver resection in HCC patients due to anemia, leucopenia, and thrombocytopenia.[@b3-ott-7-957] Although liver transplantation (LT) is an ideal treatment for these patients and can lead to acceptable long-term outcomes, especially when patients meet Milan criteria,[@b4-ott-7-957] the shortage of available organs, tumor progression in candidates on waiting lists, high costs, and graft rejection have resulted in limited LT availability for patients with HCC and hypersplenism (HCC-HSP) for whom surgical resection is an optional treatment. Recent surgical approaches and technologies have reduced complications from liver resection. Additionally, splenectomy has been shown to improve liver function[@b5-ott-7-957],[@b6-ott-7-957] and increase the safety of liver resection in certain HCC-HSP patients by reducing the possibility of bleeding complications and bilirubin overload.[@b7-ott-7-957],[@b8-ott-7-957] Therefore, simultaneous and staged hepatectomy and splenectomy are commonly performed in certain HCC-HSP patients. However, the prognostic impacts of surgical treatment for HCC-HSP patients have rarely been studied. To identify post-surgical outcomes and risk factors that can influence patient survival and tumor recurrence in HCC-HSP patients, the current authors reviewed their experiences in treating patients with HCC-HSP over the past 10 years.

Patients and methods
====================

Patients
--------

We established a database of clinicopathologic information obtained from medical records of patients who received surgery for HCC-HSP at the Department of Abdominal Surgical Oncology at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, People's Republic of China. Hypersplenism was defined as splenomegaly with a peripheral white blood cell (WBC) count of \>4 × 10^9^/L or platelet count (PLT) of \>100 × 10^9^/L. From January 1999 to February 2013, 181 consecutive patients with HCC-HSP underwent curative liver resections, defined as complete removal of all gross lesions of tumor-free margins. A pathological diagnosis of HCC was confirmed by a senior pathologist. Patients were divided into two groups: a splenectomy group (Sp group, n=60) and a non-splenectomy group (non-Sp group, n=121); that is to say, patients who had a liver resection with or without splenectomy.

Preoperative assessments
------------------------

Prior to surgery, several routine tests were performed, including but not limited to: complete blood count; liver function panel including alanine aminotransferase (ALT), aspartate aminotransferase (AST), total bilirubin (TBIL), albumin (ALB); coagulation tests including prothrombin time (PT) and activated partial thromboplastin time (APTT); hepatitis virus infection index; and α-fetoprotein (AFP). Chest radiography images were examined to exclude pulmonary metastasis. Abdominal ultrasonography (US), contrast-enhanced computed tomography (CT) scans, and magnetic resonance imaging (MRI) were used to assess tumor resectability and extent of splenomegaly. Mild splenomegaly was defined as the largest dimension of spleen \>11 cm in size; moderate splenomegaly was defined as the largest dimension of spleen 11--20 cm in size. Child-Pugh score was used to assess liver function reserve. Patients with Child-Pugh grade A, or those with grade B who were expected to recover to grade A after short-term pharmacotherapy, were eligible for surgery.

Surgical procedures
-------------------

All patients underwent conventional open surgery, including curative wedge hepatectomy, subsegmentectomy, segmentectomy, and hemihepatectomy with minimum resection margins \>1 cm. Segmentectomy and hemihepatectomy were classified as major hepatectomy; subsegmentectomy and wedge hepatectomy were classified as minor hepatectomy. In the Sp group, splenectomy was performed first, followed by hepatectomy. During liver resection, cut-ultrasound aspiration (CUSA) was used to avoid intraoperative bleeding. Hepatic inflow occlusion was used only when intrahepatic bleeding was not controllable. To prevent portal and splenic vein thrombosis (PSVT), prophylactic anticoagulant therapy, including daily injection of low molecular weight heparin over the first week after surgery and oral aspirin for 4 weeks, was regularly administered to Sp group patients.

Follow-up evaluations
---------------------

After discharge from hospital, all patients were followed every 3 months for the first 2 years, and every 6 months thereafter or when clinically indicated. Follow-up data were obtained by mail and telephone correspondence and outpatient department visits. Routine follow-up visits consisted of physical examination, routine blood tests, liver function tests, AFP levels, chest radiography, abdominal US, contrast-enhanced CT scans, and liver MRI. A diagnosis of PSVT was determined by US and CT scan results. Postoperative mortality was defined as death within 30 days of surgery. No follow-up evaluations were performed after November 30, 2013 or following death.

Statistical analyses
--------------------

Continuous variables are presented as mean ± standard deviations and compared using Mann--Whitney *U*-test or Fisher's exact test. The paired *t-*test was used to compare laboratory data. Categorical results were compared using chi-square. The Kaplan--Meier method was used to determine overall survival (OS) rates and disease-free survival (DFS). Differences in survival outcomes between the two groups were compared by log-rank test. The Cox proportional hazards model was used for multivariate analysis. *P*\<0.05 derived from two-tailed tests was considered significant. All data were analyzed using IBM SPSS version 20.0 statistics software (IBM Corporation, Armonk, NY, USA).

Results
=======

Baseline characteristics
------------------------

We investigated 181 patients ([Table 1](#t1-ott-7-957){ref-type="table"}) that included 146 males and 35 females, with an average age of 55.6±10.6 years old (median: 55 years old; range: 32--83 years old); 88.4% had hepatitis B virus infection and 87.8% had Child-Pugh grade A liver function.

Clinical characteristics
------------------------

Clinical pathological characteristics of patients from both groups were compared ([Table 2](#t2-ott-7-957){ref-type="table"}). Except for WBC count, they did not significantly differ in age, sex, Child-Pugh grade, TNM stage, extent of splenomegaly, hepatitis type, tumor location, and pre-surgery AFP levels. Although the Sp group had significantly more patients with larger tumors that required longer surgeries (*P*\<0.05), operative data, including hepatectomy type, amount of blood loss, and need for intraoperative transfusions did not significantly differ between the two groups.

Postoperative complications
---------------------------

Overall incidence of postoperative complications was 22.1%. These included wound infection, pulmonary infection, pleural effusion, ascites, gastrointestinal bleeding, intra-abdominal bleeding, and acute liver failure. Incidence of severe complications such as gastrointestinal bleeding, intra-abdominal bleeding, and acute liver failure did not significantly differ between the two groups (*P*\>0.05). Postoperative mortality was 3.9% overall and did not significantly differ between Sp (5.0%) and non-Sp groups (3.3%) (*P*\>0.05). Seven patients (11.7%) in the Sp group were diagnosed with PSVT by US or CT during routine follow-up visits but had no typical symptoms. They received anticoagulation therapy and achieved complete dissolution, as confirmed by follow-up CT ([Table 3](#t3-ott-7-957){ref-type="table"}).

Postoperative hematological variables
-------------------------------------

Patient liver function hematological variables recovered well during the study. We compared changes in liver function and HSP-related variables between the two groups. Levels of ALT, AST, and TBIL returned to normal by postoperative day (POD) 90, and there were no significant differences between the two groups (*P*\>0.05). PLT in the Sp group increased rapidly to normal levels by POD 7, and was significantly higher than the non-Sp group at PODs 7, 30, and 90 (*P*\<0.05). No patients required PLT transfusion after surgery. Although pre-surgery WBC counts were significantly lower in the Sp group compared to the non-Sp group, WBC count in the Sp group increased to normal ranges by POD 30 and was significantly higher than in the non-Sp group by POD 90 (*P*\<0.05) ([Figure 1](#f1-ott-7-957){ref-type="fig"}).

Long-term outcomes
------------------

Median follow-up duration was 25 months (range: 1--169 months). The 1, 3 and 5 year DFS rates were 67.0%, 43.8%, and 31.6%, respectively. Among the 181 patients, 97 experienced recurrence or metastasis and 60 died. Intrahepatic recurrence and metastasis was the main type of disease progression (74.2%, n=72). The most common locations of extrahepatic metastasis were lung (10.3%, n=10), bone (6.2%, n=6), and retroperitoneal lymph nodes (5.2%, n=5). The 1, 3 and 5 year OS rates were 88.4%, 67.1%, and 52.8%, respectively.

We performed subgroup analyses for survival for both groups. Among patients with stage I disease, DFS in the Sp-group (median DFS, 24.1 months; n=34) was significantly shorter than that of the non-Sp group (median DFS, 62.1 months; n=74), *P*=0.034. However, among patients with stage II disease, OS in the Sp-group (median OS, 79.1 months; n=21) was significantly better than that of the non-Sp group (median OS, 23.3 months; n=30), *P*=0.018 ([Figure 2](#f2-ott-7-957){ref-type="fig"}). Subgroup analyses found no treatment benefits in any other subgroups, including age, sex, smoking status, alcohol consumption, Child-Pugh grade, degree of splenomegaly, AFP level, and tumor location, size, or number (data not shown).

Univariate analysis
-------------------

In patients with HCC-HSP, univariate analysis showed that TNM stage, female sex, Karnofsky performance score (KPS) ≤70, multiple tumors, tumor size ≥5 cm, moderate versus (vs) mild splenomegaly, intraoperative blood transfusion, poor cell differentiation, microvascular invasion, and Child-Pugh grade B (vs A) significantly influenced DFS (*P*\<0.05); univariate analysis also showed that TNM stage, age ≥55 years old, cigarette use, tumor size ≥5 cm, moderate vs mild splenomegaly, intraoperative KPS score ≤70, blood loss, intraoperative blood transfusion, poor cell differentiation, microvascular invasion, and Child-Pugh grade B (vs A) significantly influenced OS (*P*\<0.05; [Table 4](#t4-ott-7-957){ref-type="table"}).

Multivariate analyses
---------------------

Factors found to be significant by univariate analysis were subjected to multivariate analysis to determine adjusted odds ratios ([Table 5](#t5-ott-7-957){ref-type="table"}). Results showed Child-Pugh grade B (vs A) was the only independent predictor of poor DFS (*P*=0.045), whereas independent factors for OS for patients with HCC with cirrhotic hypersplenism were age ≥55 years old, cigarette use, tumor size ≥5 cm, microvascular invasion, and Child-Pugh grade B (vs A).

Discussion
==========

In the People's Republic of China, about 85%--90% of HCC patients have liver cirrhosis, which generally results in cirrhotic hypersplenism. Incidence of hypersplenism has been found in 11% to 55% of patient deaths due to cirrhosis and portal hypertension.[@b9-ott-7-957] As surgical techniques and perioperative management approaches to preserve liver function improve, liver resection has become safer for patients with HCC and cirrhosis.[@b10-ott-7-957],[@b11-ott-7-957] Postoperative mortality and morbidity outcomes, which were acceptable in the current cohort, corresponded well with recent studies on surgical treatment strategies in HCC patients with cirrhotic hypersplenism.[@b7-ott-7-957],[@b12-ott-7-957]--[@b14-ott-7-957]

After surgery, liver function and blood cell counts recovered significantly compared to preoperative levels. Moreover, severe complications and postoperative deaths between Sp and non-Sp groups did not significantly differ. One life-threatening complication after splenectomy was overwhelming post-splenectomy infection (OPSI). Although relatively rare, OPSI has a high mortality rate.[@b15-ott-7-957] Risk factors for OPSI include splenectomy in the last three years, patients \<5 years old, and patients who have undergone splenectomy for trauma or hematologic disease.[@b16-ott-7-957]--[@b18-ott-7-957] We found no OPSI in the Sp group, probably because all SP patients were adults who had undergone splenectomy for cirrhotic hypersplenism, which is not a risk factor for OPSI. Another common complication after splenectomy was PSVT, with a reported incidence of 6%--55%.[@b19-ott-7-957]--[@b22-ott-7-957] We saw seven cases of PSVT in the Sp group (11.7%), none of them fatal. Reportedly, PSVT incidence after open splenectomy was significantly less than after laparoscopic splenectomy.[@b23-ott-7-957] In the current study, all patients underwent open surgery and received regular anticoagulant therapy afterwards, which was thought to reduce PSVT incidence.[@b20-ott-7-957],[@b22-ott-7-957]

Earlier studies have shown prognosis for HCC patients to be mainly determined by tumor burden, liver function, and performance status.[@b24-ott-7-957],[@b25-ott-7-957] Nevertheless, postoperative outcomes for HCC patients with cirrhotic hypersplenism are seldom reported. In the present study, age ≥55 years old, cigarette use, tumor size ≥5 cm, microvascular invasion, and Child-Pugh grade B (vs A) were identified as independent prognostic factors of OS by multivariate analysis, consistent with previous reports. This indicated that despite association with hypersplenism, risk predictors for HCC patient prognosis after surgery were comparable.

Among these factors, Child-Pugh grade was significantly associated with recurrence rates and long-term survival outcomes. Therefore, prior to planning surgery for HCC patients with cirrhotic hypersplenism, evaluation of liver function reserve and preoperative improvements from Child-Pugh grade B to A was critical. Moreover, patients who require Child-Pugh grade improvements should be followed-up more frequently after surgery to identify possible early recurrence.

Interestingly, cigarette smoking affected long-term outcomes in HCC patients. Studies have associated smoking with HCC development,[@b26-ott-7-957],[@b27-ott-7-957] and have attributed smoking to three major adverse effects on the liver: direct and indirect toxic effects, immunological effects, and oncogenic effects.[@b28-ott-7-957] However, confounding factors such as alcohol, genetics, the environment, and other less clearly defined factors have also been found to affect HCC development. The association between cigarette smoking and HCC-HSP calls for more clinical and basic research.

Similarly to previous studies,[@b12-ott-7-957],[@b14-ott-7-957],[@b29-ott-7-957] results from our multivariate analysis found no correlation between concomitant splenectomy and improved long-term survival in the study population. However, subgroup analysis found that DFS of the non-Sp group was longer than that of the Sp group for stage I disease patients; in contrast, concomitant splenectomy improved long-term survival of patients with stage II disease and, this finding might be explained by the anti-tumor immunological effects of the spleen. The spleen has been reported to prevent carcinogenesis in early-stage tumors, and to inhibit the tumor-induced immune response for late-stage tumors even after tumor resection.[@b13-ott-7-957] Concomitant splenectomy for patients with HCC-HSP could improve anti-tumor immune function by promoting balance in T lymphocyte subsets and T~H~1/T~H~2 cytokines.[@b30-ott-7-957],[@b31-ott-7-957] Furthermore, experiments in rat models have confirmed that positive effects of splenectomy on liver regeneration were greater in patients with larger liver resections.[@b32-ott-7-957],[@b33-ott-7-957] Therefore, it is vital to consider TNM stage when planning surgery in patients with HCC-HSP, especially for patients with stage I or II disease.

Our study was limited by its retrospective nature and sample size. Larger studies are necessary to confirm these results and explore the pathogenic mechanisms of HCC-HSP.

Conclusion
==========

Age ≥55 years old, cigarette smoking, tumor size ≥5 cm, microvascular invasion, and Child-Pugh grade B were independent negative predictors of OS in patients with HCC-HSP. Spleen-preserving strategies could improve DFS of patients with stage I HCC-HSP, whereas concomitant splenectomy (vs hepatectomy only) could prolong survival for patients with stage II disease.
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![Changes in results of laboratory tests.\
**Notes:** Changes in results of laboratory tests between Sp and non-Sp groups. (**A** and **B**). WBC and PLT levels of the Sp group increased significantly at PODs 7, 30, and 90 compared to those of the non-Sp group, \**P*\<0.05 (**C**--**E**). Levels of TBIL, ALT, and AST returned to normal by POD 90 and did not differ between the two groups, \**P*\>0.05.\
**Abbreviations:** Sp, splenectomy; WBC, white blood cell; PLT, platelet; POD, post-operative day; TBIL, total bilirubin; ALT, alanine aminotransferase; AST, aspartate aminotransferase; preop, preoperative.](ott-7-957Fig1){#f1-ott-7-957}

![(**A**) Kaplan--Meier survival curves of DFS for patients with HCC and hypersplenism at TNM stage I who were treated with concomitant splenectomy (n=74) and without splenectomy (n=34), *P*=0.034. (**B**) Kaplan--Meier survival curves of OS for patients with HCC and hypersplenism at TNM stage II who were treated with concomitant splenectomy (n=21) and without splenectomy (n=30), *P*=0.018.\
**Abbreviations:** HCC, hepatocellular carcinoma; DFS, disease-free survival; OS, overall survival; TNM, tumor lymph node metastasis.](ott-7-957Fig2){#f2-ott-7-957}

###### 

Clinical characteristics of patients with HCC and hypersplenism

  Variable                                        N     (%)
  ----------------------------------------------- ----- ------
  Sex                                                   
   Male                                           146   80.7
   Female                                         35    19.3
  Age                                                   
   \<55 years                                     78    43.1
   ≥55 years                                      103   56.9
  KPS                                                   
   90--100                                        99    54.7
   80                                             49    27.1
   60--70                                         33    18.2
  Smoking                                               
   No                                             110   60.8
   Yes                                            71    39.3
  Alcohol consumption                                   
   No                                             108   59.7
   Yes                                            73    40.3
  Diabetes                                              
   No                                             164   90.6
   Yes                                            17    9.4
  Etiology                                              
   HBV                                            160   88.4
   HCV                                            9     5.0
   HBV and HCV                                    4     2.2
   None                                           8     4.4
  Family history of HCC                                 
   No                                             147   81.2
   Yes                                            34    18.8
  AFP level                                             
   \<20 ng/mL                                     67    36.0
   ≥20 ng/mL                                      114   63.0
  Child-Pugh grade                                      
   A                                              159   87.8
   B                                              22    12.2
  Splenomegaly                                          
   Mild                                           173   95.6
   Moderate                                       8     4.4
  Splenectomy                                           
   No                                             121   66.9
   Yes                                            60    33.1
  TNM stage                                             
   I                                              108   59.7
   II                                             51    28.2
   III                                            16    8.8
   IV[\*](#tfn1-ott-7-957){ref-type="table-fn"}   6     3.3

**Note:**

Case of distant metastasis was excluded.

**Abbreviations:** HCC, hepatocellular carcinoma; HBV, hepatitis B virus; HCV, hepatitis C virus; AFP, α-fetoprotein; KPS, Karnofsky performance score; TNM, tumor lymph node metastasis.

###### 

Comparison of clinical and pathological characteristics of HCC patients with hypersplenism in non-Sp and Sp groups

                                              Non-Sp group (n=121)   Sp group (n=60)   *P*-value
  ------------------------------------------- ---------------------- ----------------- -----------
  Sex, male/female                            100/21                 46/14             0.338
  Age, years old                              55.8±11.0              55.2±9.8          0.282
  Etiology, HBV/HCV/both/none                 105/9/2/6              55/0/2/2          0.148
  Child-Pugh grade, A/B                       107/14                 52/8              0.733
  Splenomegaly, mild/moderate                 117/4                  56/4              0.300
  AFP, \<20/≥20 ng/mL                         48/73                  19/41             0.294
  WBC count, ×10^9^/L                         4.3±1.4                3.4±0.8           0.002
  PLT count, ×10^9^/L                         88.3±29.8              70.5±21.6         0.184
  Minor/major hepatectomy                     95/26                  49/11             0.620
  Operation time, minutes                     158±64                 221±86            0.030
  Intraoperative blood loss, mL               759±1,113              882±1,997         0.402
  Intraoperative blood transfusion, no/yes    51/70                  28/32             0.564
  Tumor location, left/right lobe             27/94                  17/43             0.374
  Tumor size,\<5 cm/≥5 cm                     72/49                  47/13             0.012
  Tumor number, solitary/multiple             102/19                 47/13             0.322
  TNM stage, I/II/III/IV                      74/30/12/5             34/21/4/1         0.418
  Pathological margin, \<1 cm/≥1 cm           114/7                  57/3              0.828
  Differentiation, well + moderately/poorly   76/45                  42/18             0.339
  Microvascular invasion, no/yes              112/9                  55/5              0.832

**Note:** Values are expressed as mean ± standard deviation.

**Abbreviations:** HCC, hepatocellular carcinoma; Sp, splenectomy; AFP, α-fetoprotein; WBC, white blood cell; PLT, platelet; TNM, tumor lymph node metastasis; HBV, hepatitis B virus; HCV, hepatitis C virus.

###### 

Postoperative complications of patients with HCC and hypersplenism

  Variables                          Non-Sp group (n=121)   Sp group (n=60)   *P*-value
  ---------------------------------- ---------------------- ----------------- -----------
  Postoperative complications                                                 0.778
   Wound infection                   4                      1                 
   Pulmonary infection               3                      1                 
   Pleural effusion                  3                      2                 
   Ascites                           6                      3                 
   Upper gastrointestinal bleeding   2                      2                 
   Intra-abdominal bleeding          2                      1                 
   Acute liver failure               3                      2                 
   PSVT                              0                      7                 
  Perioperative deaths               4                      3                 0.687

**Abbreviations:** HCC, hepatocellular carcinoma; Sp, splenectomy; PSVT, portal of splenic vein thrombosis.

###### 

Univariate analysis of DFS and OS for HCC patients with hypersplenism

  Variables                          DFS                  OS                            
  ---------------------------------- -------------------- --------- ------------------- -------
  TNM stage                          1.77 (1.41--2.22)    \<0.001   1.50 (1.13--2.00)   0.005
  Sex, female                        0.46 (0.23--0.89)    0.021     0.70 (0.33--1.49)   0.359
  Age, ≥55 years old                 1.18 (0.79--1.78)    0.419     1.73 (1.00--2.98)   0.049
  KPS, ≤70                           1.23 (1.04--1.47)    0.016     1.26 (1.01--1.57)   0.038
  Cigarette smoking                  1.35 (0.90--2.02)    0.147     1.73 (1.03--2.89)   0.037
  Alcohol consumption                1.15 (0.76--1.72)    0.511     1.50 (0.90--2.49)   0.117
  Diabetes                           1.30 (0.69--2.43)    0.421     1.32 (0.60--2.91)   0.490
  Family history                     0.96 (0.72--1.27)    0.760     0.87 (0.62--1.22)   0.408
  Tumor number, multiple             1.65 (1.00--2.71)    0.048     1.24 (0.64--2.41)   0.520
  Tumor size, ≥5 cm                  2.13 (1.41--3.22)    \<0.001   2.08 (1.24--3.49)   0.006
  Tumor location, right              0.80 (0.51--1.24)    0.313     0.72 (0.41--1.27)   0.255
  Splenomegaly, moderate             4.66 (1.99--10.87)   \<0.001   3.09 (1.11--8.59)   0.031
  Splenectomy                        1.28 (0.85--1.95)    0.241     1.01 (0.58--1.77)   0.960
  Intraoperative blood loss          1.33 (0.87--2.01)    0.184     1.79 (1.07--2.99)   0.026
  Intraoperative blood transfusion   1.61 (1.06--2.42)    0.025     2.19 (1.27--3.77)   0.005
  Hepatic inflow occlusion           0.87 (0.44--1.73)    0.684     0.56 (0.17--1.79)   0.326
  Differentiation, poorly            1.64 (1.05--2.58)    0.031     2.06 (1.16--3.67)   0.014
  Microvascular invasion             4.28 (2.25--8.14)    \<0.001   3.58 (1.74--7.33)   0.001
  Child-Pugh grade, B                2.05 (1.10--3.81)    0.023     3.38 (1.56--7.35)   0.002
  AFP level, ≥20 ng/mL               1.16 (0.76--1.77)    0.502     1.74 (0.99--3.06)   0.056

**Abbreviations:** HCC, hepatocellular carcinoma; DFS, disease-free survival; OS, overall survival; KPS, Karnofsky performance score; HR, hazard ratio; CI, confidence interval; AFP, α-fetoprotein; TNM, tumor lymph node metastasis.

###### 

Multivariate analysis of DFS and OS for HCC patients with hypersplenism

  Prognostic factor        DFS                  OS                           
  ------------------------ -------------------- ------- -------------------- -------
  Age, ≥55 years old       /                    /       2.07 (1.10--3.92)    0.025
  Cigarette smoking        /                    /       1.87 (1.03--3.39)    0.039
  Tumor size, ≥5 cm        /                    /       2.93 (1.37--6.26)    0.005
  Microvascular invasion   /                    /       5.09 (1.61--16.05)   0.006
  Child-Pugh grade, B      2.245 (1.02--4.95)   0.045   4.88 (1.78--13.37)   0.002

**Abbreviations:** HCC, hepatocellular carcinoma; DFS, disease-free survival; OS, overall survival; HR, hazard ratio; CI, confidence interval.
